Research Grade Teropavimab

Catalog No.

DVV03104

Expression system

Mammalian Cells

Species reactivity

Human immunodeficiency virus 1 (HIV-1)

Host species

Humanized

Isotype

IgG1-kappa

Clonality

Monoclonal

Target

gp120/Glycoprotein 120

Concentration

1.04 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q03805

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

30 mM histidine pH 5.8, 10% sucrose, 0.02% Tween 80

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

3BNC117-LS, GS-5423 CAS: 2417213-72-8

Clone ID

Teropavimab

Lenacapavir Plus Two Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab., PMID:40176256

Susceptibility to lenacapavir, fostemsavir and broadly neutralizing antibodies in French primary HIV-1 infected patients in 2020-2023., PMID:39363782

Susceptibility Screening of HIV-1 Viruses to Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, in People With HIV-1 Suppressed by Antiretroviral Therapy., PMID:39298557

Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study., PMID:38307098

Broadly neutralizing antibodies and long-acting antiretroviral drugs as treatments for HIV., PMID:37265259

Document Download

Research Grade Teropavimab.pdf